Revenue and Profitability - Revenue for Q1 2024 was CNY 218,746,520.01, an increase of 9.54% compared to CNY 199,699,286.27 in the same period last year[3] - Net profit attributable to shareholders was a loss of CNY 5,987,478.11, a decrease of 172.85% from a profit of CNY 8,219,096.97 in the previous year[3] - The net profit for the current period was a loss of ¥9,014,292.30, compared to a profit of ¥6,162,715.32 in the previous period, indicating a significant decline[22] - The total comprehensive income for the current period was a loss of ¥9,014,292.30, compared to a profit of ¥6,162,715.32 in the previous period, indicating a substantial decline[22] - The basic earnings per share for the current period was -0.01, compared to 0.02 in the previous period, reflecting a negative shift[23] Cash Flow and Financial Position - Net cash flow from operating activities decreased by CNY 82,149,625.11, down 145.37% compared to CNY -33,479,624.14 in the same period last year[3] - Cash flow from operating activities showed a net outflow of ¥82,149,625.11, worsening from a net outflow of ¥33,479,624.14 in the previous period[25] - The company's cash and cash equivalents decreased to CNY 230,906,156.49 from CNY 295,125,324.59, representing a decline of about 21.8%[17] - Cash and cash equivalents at the end of the period totaled ¥107,104,540.10, down from ¥202,116,081.26, indicating a decrease of approximately 47%[26] Assets and Liabilities - Total assets at the end of the reporting period were CNY 2,549,802,979.79, a decrease of 1.85% from CNY 2,597,903,543.28 at the end of the previous year[3] - The company's total liabilities decreased to CNY 1,509,705,178.58 from CNY 1,541,931,449.79, reflecting a decline of about 2.1%[19] - Total current liabilities decreased to CNY 1,303,959,344.49 from CNY 1,338,384,281.52, a decrease of approximately 2.6%[18] - The total equity attributable to shareholders decreased to CNY 1,009,692,706.36 from CNY 1,015,680,184.47, a decrease of approximately 0.7%[19] Expenses and Financial Management - The company reported a significant increase in financial expenses, which rose by 596.58% to CNY 287,010.00 due to higher interest expenses[7] - The company reported a significant increase in financial expenses, which rose to ¥3,351,178.63 from ¥481,091.95, marking an increase of over 600%[21] - Total operating costs increased to ¥230,505,235.10 from ¥198,382,700.24, representing a rise of about 16.2%[21] - Research and development expenses were ¥18,856,693.84, slightly down from ¥19,521,806.32, showing a decrease of about 3.4%[21] Shareholder Information - The number of ordinary shareholders at the end of the reporting period was 28,173[9] Government Support and Certification - The company received government subsidies amounting to CNY 614,995.89 during the reporting period[4] - The company received high-tech enterprise certification for its subsidiaries, indicating a focus on innovation and technology development[13] Corporate Developments - The company is in the process of restructuring its subsidiary Shanghai Kaixian Fluid Technology Co., Ltd. and applying for listing on the New Third Board, which may enhance its market presence[15] - The company has completed the registration change and obtained a new business license, indicating ongoing operational adjustments[14] Reporting and Standards - The first quarter report has not been audited[27] - The new accounting standards will be implemented starting in 2024[27] - The board meeting was held on April 25, 2024[28]

证券代码：300412 证券简称：迦南科技 公告编号：2024-039 浙江迦南科技股份有限公司 第五届监事会第二十次会议决议公告 浙江迦南科技股份有限公司（以下简称"公司"）第五届监事会第二十次会 议通知于 2024 年 4 月 18 日以微信、电话及电子邮件等通讯方式送达全体监事 2、会议召开的时间、方式和表决情况 （1）会议时间：2024 年 4 月 25 日下午 （2）召开地点：公司会议室 （3）召开方式：以现场结合通讯方式召开 （4）主持人：监事会主席王虎根先生 本公司及监事会全体成员保证信息披露内容的真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏。 一、监事会会议召开情况 1、会议通知时间与方式 2024 年 4 月 25 日 300412 1、审议通过《关于 2024 年第一季度报告的议案》 表决结果：3 票同意，0 票反对，0 票弃权。 经审核，监事会认为董事会编制和审核公司 2024 年第一季度报告的程序符 合法律、行政法规和中国证监会的规定，报告内容真实、准确、完整地反映了公 司的实际情况，不存在任何虚假记载、误导性陈述或者重大遗漏。 特此公告。 具体内容详见同日披露在巨潮资讯网的 ...

证券代码：300412 证券简称：迦南科技 公告编号：2024-036 浙江迦南科技股份有限公司 关于调整子公司股权结构的进展公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏。 浙江迦南科技股份有限公司（以下简称"公司"）于 2023 年 10 月 25 日召开 了第五届董事会第十五次会议和第五届监事会第十五次会议，审议通过了《关于 调整子公司股权结构的议案》，公司全资子公司迦楠（天津）科技有限公司（以 下简称"天津迦楠"）拟吸收合并莱米特（天津）科技有限公司（以下简称"天津 莱米特"）。本次吸收合并完成后，天津莱米特的独立法人资格将被注销，其全 部资产、负债、权益、业务等将由天津迦楠承继。具体内容详见 2023 年 10 月 27 日刊登在巨潮资讯网的相关公告（公告编号：2023-052）。 二、进展情况 近日，天津莱米特已完成相关工商登记注销手续，与此同时天津迦楠完成 了工商变更登记手续，并取得了新的《营业执照》，具体内容如下： 名 称：迦楠（天津）科技有限公司 统一社会信用代码：91120222MABLLHU241 法定代表人：王洪海 注册资本：伍仟叁 ...

北京德恒（杭州）律师事务所 关于浙江迦南科技股份有限公司 2024 年第三次临时股东大会的 法律意见书 杭州市上城区新业路 200 号华峰国际商务大厦 10-11 楼 电话:0571-86508080 传真:0571-87357755 邮编:310020 北京德恒（杭州）律师事务所 关于浙江迦南科技股份有限公司 2024 年第三次临时股东大会的法律意见书 北京德恒（杭州）律师事务所 关于浙江迦南科技股份有限公司 2024年第三次临时股东大会的 法律意见书 2024 年 3 月 28 日，公司第五届董事会第十八次会议审议通过了《关于召开 1 北京德恒（杭州）律师事务所 关于浙江迦南科技股份有限公司 2024 年第三次临时股东大会的法律意见书 2024 年第三次临时股东大会的议案》，本次股东大会的召集人是公司董事会。 德恒【杭】书（2024）第04029号 致：浙江迦南科技股份有限公司 根据《中华人民共和国公司法》（以下简称"《公司法》"）、《中华人 民共和国证券法》（以下简称"《证券法》"）和中国证券监督管理委员会关 于《上市公司股东大会规则》（以下简称"《股东大会规则》"）等法律、法 规和其他有关规范性文件的 ...

证券代码：300412 证券简称：迦南科技 公告编号：2024-035 浙江迦南科技股份有限公司 2024 年第三次临时股东大会决议公告 （1）通过深圳证券交易所交易系统进行网络投票的时间为 2024 年 4 月 23 日 9:15—9:25，9:30—11:30 和 13:00—15:00； （2）通过深圳证券交易所互联网系统投票的具体时间为 2024 年 4 月 23 日 9:15-15:00。 2、现场会议召开地点：浙江省温州市永嘉县瓯北街道江楠大道 1188 号公司 会议室； 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏。 特别提示： 1、本次股东大会未出现否决议案的情况； 2、本次股东大会召开期间没有增加或变更议案，不涉及变更以往股东大会 已通过的决议。 一、会议召开和出席情况 （一）会议召开情况 1、会议时间: 现场会议召开时间：2024 年 4 月 23 日（周二）下午 13:30； 网络投票时间： 3、召开方式：采取现场投票与网络投票相结合的方式； 4、召 集 人：公司董事会； 5、主 持 人：董事长方正先生； 6、本次股东大会的召集、召开程序 ...

Financial Performance - The company reported a significant loss for the year, primarily due to a decrease in gross margins for certain products and an increase in operating expenses[4]. - The company's operating revenue for 2023 was ¥1,047,093,891.26, a decrease of 5.11% compared to ¥1,103,431,012.50 in 2022[20]. - The net profit attributable to shareholders was -¥23,433,467.29, an improvement of 68.84% from -¥75,201,420.17 in the previous year[20]. - The net cash flow from operating activities was -¥62,974,373.07, a significant decline of 191.78% compared to ¥68,616,352.64 in 2022[20]. - The total assets at the end of 2023 amounted to ¥2,597,903,543.28, reflecting a 3.91% increase from ¥2,500,027,855.85 at the end of 2022[20]. - The company's basic earnings per share improved to -¥0.05 from -¥0.15 in 2022, representing a 66.67% increase[20]. - The company reported a total of ¥14,237,879.17 in non-recurring gains and losses for 2023, compared to ¥10,196,641.20 in 2022[26]. Strategic Focus and Future Plans - The company plans to focus on its core business to enhance its industry position, competitive capabilities, and sustainable development[4]. - The company aims to improve its profitability through various measures as detailed in the management analysis section[4]. - Future plans and projections mentioned in the report do not constitute a commitment to investors, highlighting the need for risk awareness[4]. - The company is committed to enhancing its operational performance moving forward[4]. - The company aims to transform into a comprehensive solution provider, integrating process development, equipment procurement, and project application services for pharmaceutical enterprises[45]. - The company anticipates that the growth of oral solid dosage equipment, intelligent factory projects, and the rapid development of the pharmaceutical outsourcing and testing industry will drive its performance in the future[47]. Market and Industry Insights - The global pharmaceutical market is expected to continue growing due to factors such as population increase and rising health awareness[31]. - The global pharmaceutical market is expected to grow at a CAGR of 3%-6% to reach $1.6 trillion by 2025, with oncology drugs projected to exceed $260 billion by 2025, growing at a CAGR of 9%-12%[32]. - China's pharmaceutical market size is expected to reach RMB 172.92 billion in 2021, with a CAGR of 5.4% from 2016 to 2021, and projected to grow at a CAGR of 7.2% to RMB 228.73 billion by 2025[33]. - The pharmaceutical equipment industry is characterized by rigid demand, with no significant cyclical or seasonal features[29]. - The pharmaceutical equipment industry in China has seen significant growth, with over 6,000 pharmaceutical production enterprises undergoing GMP certification since 1999, leading to improved technology and product quality[39]. Risk Management - The company has outlined potential risks in its operations and corresponding mitigation strategies in the management discussion section[6]. - The report emphasizes the importance of understanding the differences between plans, forecasts, and commitments[4]. - The company faces risks from policy changes in the pharmaceutical industry that could impact demand for its products[117]. - The company is addressing market competition risks by enhancing R&D investment and maintaining advanced technology and production standards[118]. Research and Development - The company has developed a comprehensive pharmaceutical R&D and testing system, providing high-cost performance solutions for rapid and reliable R&D and testing services[45]. - The company is currently testing a series of new technologies, including a liquid filtration and drying machine, which aims to improve product safety and efficiency[79]. - The company has focused on enhancing the reliability of its products through the development of a capsule filling machine powder collection device, which aims to reduce production costs[80]. - R&D investment amounted to ¥83,766,557.46 in 2023, representing 8.00% of operating revenue, an increase from 7.27% in 2022[80]. Governance and Compliance - The company has a governance structure that protects the rights of all shareholders, particularly minority shareholders, ensuring compliance with legal and regulatory requirements[128]. - The company’s board consists of 7 members, including 3 independent directors, fulfilling legal and regulatory requirements for board composition[129]. - The company has maintained a consistent shareholding structure with no significant changes reported in the ownership distribution[136]. - The internal control evaluation report indicated that the company maintained effective internal controls related to financial reporting as of December 31, 2023[164]. Employee and Human Resources - The total number of employees at the end of the reporting period is 1,749, with 647 in the parent company and 1,102 in major subsidiaries[151]. - The company emphasizes a performance-based compensation policy, linking salaries to individual and team performance while ensuring compliance with labor laws[152]. - Training programs are tailored to enhance employee skills and align with the company's strategic goals, including various types of training such as onboarding and management training[153]. Community and Investor Relations - The company actively communicates with investors through various channels, including phone, email, and its website[169]. - The company maintains a commitment to investor returns, implementing a transparent profit distribution policy that includes cash dividends[155]. - The company has not proposed any cash dividend distribution despite having positive distributable profits, citing the need for stable operations and risk resistance[158].

国投证券股份有限公司 关于浙江迦南科技股份有限公司 开展外汇衍生品及商品期货套期保值业务的核查意见 国投证券股份有限公司（以下简称"国投证券"、"保荐机构"）作为浙江 迦南科技股份有限公司（以下简称"迦南科技"、"上市公司"或"公司"）2020 年度向特定对象发行股票的保荐机构，根据《证券发行上市保荐业务管理办法》 《深圳证券交易所创业板股票上市规则》《深圳证券交易所上市公司自律监管指 引第 2 号——创业板上市公司规范运作》等有关规定，对迦南科技开展外汇衍生 品及商品期货套期保值业务的事项进行了核查，核查情况及核查意见如下： 一、开展外汇衍生品交易及商品期货套期保值业务的目的 随着公司日常经营中出口业务规模逐渐增长，为有效规避和防范公司因进出 口业务带来的潜在汇率等风险，公司拟与银行等金融机构开展外汇衍生品交易业 务，提高外汇资金使用效率，合理降低财务费用，减少汇率波动的影响。同时， 公司作为制药装备的生产研发和销售企业，需要进行原材料采购，为规避原材料 价格大幅度波动给公司经营带来的不利影响，公司拟以自有资金进行钢材等商品 期货的套期保值业务，有效管理价格大幅波动的风险。 二、开展外汇衍生品交易及商品期货 ...

关于浙江迦南科技股份有限公司 2024 年度使用闲置自有资 金和闲置募集资金进行现金管理的核查意见 国投证券股份有限公司（以下简称"国投证券"、"保荐机构"）作为浙江迦 南科技股份有限公司（以下简称"公司"、"迦南科技"）2020 年度向特定对象发 行股票的保荐机构，根据《上市公司监管指引第 2 号——上市公司募集资金管理 和使用的监管要求》《深圳证券交易所创业板股票上市规则》《深圳证券交易所上 市公司自律监管指引第 2 号——创业板上市公司规范运作》等相关法律、法规和 规范性文件的规定，对迦南科技及其控股子公司拟使用闲置募集资金和闲置自有 资金进行现金管理的事项进行了审慎核查，核查的具体情况如下： 一、募集资金基本情况 经中国证券监督管理委员会《关于同意浙江迦南科技股份有限公司向特定对 象发行股票注册的批复》（证监许可[2021]1175 号），同意公司向特定对象发行股 票的注册申请。公司向 12 名特定对象发行人民币普通股（A 股）股票 35,573,122 股，发行价格 7.59 元/股，募集资金总额为人民币 269,999,995.98 元，扣除各项 发行费用人民币 8,137,735.84 元（不含 ...

浙江迦南科技股份有限公司 2023 年度独立董事述职报告 （樊德珠） 各位股东及股东代表： 本人作为浙江迦南科技股份有限公司（以下简称"公司"）的独立董事，2023 年度，严格按照《公司法》、《上市公司治理准则》、《上市公司独立董事管理 办法》和《深圳证券交易所上市公司自律监管指引第 2 号——创业板上市公司规 范运作》等有关法律法规以及《公司章程》、《公司独立董事工作制度》的规定 和要求，勤勉尽职、恪尽职守，积极出席股东大会、董事会和董事会各专门委员 会会议，认真审议各项议案，从专业角度为公司的经营决策和规范运作提出独立 意见与合理化建议，努力维护公司的整体利益和股东尤其是中小股东的合法权益。 现将 2023 年度履行独立董事职责情况汇报如下： 一、独立董事的基本情况 （一）独立董事工作履历、专业背景及兼职情况 本人樊德珠，1966 年出生，研究生学历，高级律师，中国国籍，无境外永 久居留权。曾任杭州民生财团、浙江中大控股集团有限公司总裁办经理、浙江钱 江律师事务所合伙人、律师；现任浙江锦丰律师事务所主任，浙江省律协常务理 事、浙江省律协执业权益保障委员会副主任、浙江省律协女律师工作委员会主任、 杭州市第十 ...

我们接受委托，审计了浙江迦南科技股份有限公司(以下简称迦南科技公 司)2023年度财务报表，并于2024年4月18日出具中汇会审[2024]4207号无保留意见 的审计报告，在此基础上对后附的迦南科技公司管理层编制的《浙江迦南科技股份 有限公司2023年度营业收入扣除情况表》(以下简称营业收入扣除情况表)进行了审 核。 一、管理层的责任 管理层的责任是提供真实、合法、完整的相关资料，按照《深圳证券交易所创 业板股票上市规则(2023年8月修订)》以及《深圳证券交易所创业板上市公司自律 监管指南第1号——业务办理(2023年11月修订)》的规定编制营业收入扣除情况表 以满足监管要求，并负责设计、执行和维护必要的内部控制，并保证其内容真实、 准确、完整，不存在虚假记载、误导性陈述和重大遗漏。 二、注册会计师的责任 我们的责任是在执行审计工作的基础上对迦南科技公司管理层编制的营业收 入扣除情况表发表专项审核意见。中国注册会计师审计准则要求我们遵守中国注册 会计师职业道德守则，计划和执行审计工作以对营业收入扣除情况表是否不存在重 大错报获取合理保证。 关于浙江迦南科技股份有限公司 2023年度营业收入扣除情况的专项审 ...